- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03057457
The NGAL Test™ As An Aid in the Risk Assessment for AKI Stage II and III in an Intensive Care Population
The NGAL TestTM is a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human EDTA plasma for testing on automated clinical chemistry analyzer.
The First Indication for Use: An NGAL test result above the assay cutoff as an aid in the risk assessment for the development of stage II or III acute kidney injury (AKI) within 1 day of patient assessment in patients in the intensive care unit (ICU) who are hypotensive (MAP<70 mmHg) and/or receiving vasopressor support. Second Indication for Use: In patents with stage II or III AKI, NGAL measurement aids in the risk assessment of the development of persistent (≥2 days) stage 2 or 3 AKI.
The Primary Objective for this clinical trial is to validate that the NGAL test using a cutoff of 140 ng/ml shows clinical performance in predicting the development of moderate or severe acute kidney injury within 1 day. The Secondary Objective is to validate that the NGAL test shows clinical performance in predicting persistent moderate or severe acute kidney injury during any contiguous 2 day interval.
It is anticipated that up to 20 Clinical Sites in US will participate in the trial. The study sites will recruit consecutive patients meeting the inclusion and exclusion criteria who are admitted to hospital in an ICU or critical care setting. Patients will receive their clinical standard of care including standard laboratory and other testing as requested by each subject's physician.
Study Overview
Detailed Description
The NGAL TestTM is a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human EDTA plasma for testing on automated clinical chemistry analyzer.
The First Indication for Use: An NGAL test result above the assay cutoff as an aid in the risk assessment for the development of stage II or III acute kidney injury (AKI) within 1 day of patient assessment in patients in the intensive care unit (ICU) who are hypotensive (MAP<70 mmHg) and/or receiving vasopressor support. Second Indication for Use: In patents with stage II or III AKI, NGAL measurement aids in the risk assessment of the development of persistent (≥2 days) stage 2 or 3 AKI.
The Primary Objective for this clinical trial is to validate that the NGAL test using a cutoff of 140 ng/ml shows clinical performance in predicting the development of moderate or severe acute kidney injury within 1 day. The Secondary Objective is to validate that the NGAL test shows clinical performance in predicting persistent moderate or severe acute kidney injury during any contiguous 2 day interval.
It is anticipated that up to 20 Clinical Sites in the US will participate in the trial. The study sites will recruit consecutive patients meeting the inclusion and exclusion criteria who are admitted to hospital in an ICU or critical care setting. Patients will receive their clinical standard of care including standard laboratory and other testing as requested by each subject's physician. Enrollment is estimated to take approximately six months and the trial will be stopped when the Adjudication Panel has diagnosed at least 85 patients with AKI stage 2 or 3.
Each subject who is enrolled in the study will only have 4 blood draws as part of NGAL TestTM Trial with no additional study activities with the exception of data collection. The NGAL results will not be returned to the treating physician for use in the health management of the study subjects.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Patsy Folio
- Phone Number: 480-735-9035
- Email: patsy.folio@precisionformedicine.com
Study Contact Backup
- Name: Natalia Escuti, MD
- Phone Number: 818 481 2248
- Email: natalia.escuti@precisionformedicine.com
Study Locations
-
-
Colorado
-
Denver, Colorado, United States, 80218
- Recruiting
- Colorado Kidney Care
-
Contact:
- Melanie Foster-Schwartz
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Brock Katherine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
• Subjects should be enrolled within 24 hrs. of ICU admission, from ED or floor within 24 hrs. of ICU admission or if the subject is from another ICU no more than 24 hrs. from presentation.
Within 24 hrs. prior to enrollment the subject's
o Cardiovascular SOFA score of >= 1(MAP<70 mmHg and/or receiving any vasopressor support
- Subject or representative written informed consent
- Subject > 18 years of age
Exclusion Criteria:
- If the subject is part of a special population (pregnancy, prisoners)
- If the subject has received a previous renal transplantation
- If the subject has been diagnosed with moderate to severe AKI prior to enrollment as defined by the treating physician (KDIGO Stage 2/3, RIFLE-I or RIFLE-F/AKIN 2 or AKIN 3) ,
- If the subject is currently on dialysis or in imminent need of dialysis at the time of enrollment
- The subject has been diagnosed with HIV or Hepatitis
- The subject has been diagnosed with Chronic Kidney disease without baseline value - CKD stage 4-5
- If the patient is on palliative care
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Kidney Injury
|
The purpose of this study is to demonstrate that BioPorto Diagnostic's NGAL test is able to assist in determining the risk for acute kidney injury for patients who have been admitted to the intensive care unit.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sensitivity and Specificity
Time Frame: Up to 7 days in ICU or until discharge
|
To demonstrate that the sum of sensitivity and specificity is greater than 1 using a cutoff of 140 ng/mL when compared to the primary clinical endpoint AKI as adjudicated KDIGO Stage 2/3 AKI
|
Up to 7 days in ICU or until discharge
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- NGAL-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Injury
-
Instituto Nacional de Cardiologia Ignacio ChavezInstituto Nacional de Ciencias Medicas y Nutricion Salvador ZubiranUnknownKidney Injury, Acute | Acute Renal Injury | Acute Kidney Injuries | Kidney Injuries, Acute | Acute Renal InjuriesMexico
-
Mayo ClinicCompletedKidney InjuryUnited States
-
Hospital Medina del CampoCompleted
-
University of PittsburghRenalSense LtdCompletedAcute Kidney Injury | Kidney InjuryUnited States
-
Community Medical Center, Scranton, PACompleted
-
Tel-Aviv Sourasky Medical CenterNot yet recruiting
-
Yonsei UniversityCompletedAcute Kidney Injury(Postoperative Acute Kidney Injury in Patients Undergoing Aortic Surgery)Korea, Republic of
-
University Hospital, GhentWithdrawn
-
University of NottinghamNot yet recruitingKidney Diseases | Ultrasonography | Kidney Injury, Acute | Perfusion ImagingUnited Kingdom
-
Beni-Suef UniversityCairo UniversityRecruitingAKI - Acute Kidney InjuryEgypt
Clinical Trials on NGAL Test
-
Kasr El Aini HospitalCompletedAnemia | Acute Kidney InjuryEgypt
-
Assiut UniversityNot yet recruitingMultiple Myeloma(MM)
-
Uijeongbu St. Mary HospitalRecruitingOut-of-Hospital Cardiac ArrestKorea, Republic of
-
The AlfredBiositeCompleted
-
Fondation LenvalCompleted
-
Centre Hospitalier Universitaire de NīmesCompletedAcute Kidney Failure | RhabdomyolysisFrance
-
Yonsei UniversityUnknownPost Cardiac Arrest Patient Who Was Treated by Hypothermia ProtocolKorea, Republic of
-
Sheba Medical CenterZotal Inc.UnknownNo-Reflow Phenomenon | STEMI - ST Elevation Myocardial InfarctionIsrael
-
Antalya Training and Research HospitalCompletedProstatectomyTurkey